Who we are
Cardio3 BioSciences, headquartered in Mont-Saint-Guibert (Belgium), is a biopharmaceutical company, founded in 2007, and focused on the discovery, development and commercialization of regenerative and protective therapies for cardiovascular diseases.
The aim of these therapies is to protect the heart during myocardial injury, reduce the volume of the scar and reconstruct damaged heart tissue. Current therapies palliate symptoms rather than address loss of viable functional myocardium, which is the root cause of heart failure (HF).
The Company’s focus is on developing novel regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury.
Cardio3 BioSciences’ product candidates and research programmes are based on the breakthrough proprietary Cardiopoiesis technology platform, which is based on fundamental research conducted at Mayo Clinic.